11.04.2016
STRATEC Biomedical AG DE000STRA555
DGAP-News: STRATEC proposes increase of dividend to EUR 0.75 per share
DGAP-News: STRATEC Biomedical AG / Key word(s): Dividend
STRATEC proposes increase of dividend to EUR 0.75 per share
11.04.2016 / 14:23
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STRATEC proposes increase of dividend to EUR 0.75 per share
Birkenfeld, April 11, 2016
The Board of Management and Supervisory Board of STRATEC Biomedical AG
(Frankfurt: SBS; Prime Standard, TecDAX) at their meeting held today
approved the recommendation submitted by the Board of Management to propose
the payment of a dividend of EUR 0.75 per share for the 2015 financial year
for approval by the Annual General Meeting on June 9, 2016 (distribution in
previous year: EUR 0.70 per share). Based on the current total of
11,846,280 shares with dividend entitlement, the proposal corresponds to a
7.7% increase in the distribution total to EUR 8.885 million (previous
year: EUR 8.248 million). STRATEC continues to follow its
shareholder-friendly and continuity-based dividend policy. If approved,
this year's dividend would be the twelfth consecutive increase in the
distribution to shareholders since dividends were first paid in 2004.
Based on preliminary figures announced on March 15, 2016, STRATEC
Biomedical AG increased its sales by 1.4% to EUR 146.9 million in the 2015
financial year. The EBIT margin rose significantly from 16.6% in the
previous year to 18.3%. The final audited results for the 2015 financial
year will be published on April 14, 2016.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
[email protected]
www.stratec.com
---------------------------------------------------------------------------
11.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: [email protected]
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX
End of News DGAP News Service
---------------------------------------------------------------------------
453105 11.04.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
STRATEC Biomedical AG ISIN: DE000STRA555 können Sie bei EQS abrufen
Medtech , STRA55 , SBS , XETR:SBS